Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Zeria’s Acinon Now Sole Nizatidine Product Being Shipped as Yoshindo Launches Recall
January 13, 2023
- Janssen Vows to Offer New Positions for Employees Shown Exit Door: 1st Labor Talks
January 13, 2023
- Ferring to Take Over Gonax’s Japan Authorization from Astellas
January 13, 2023
- Xofluza Adds Pediatric Indication in Europe: Roche
January 13, 2023
- Alfresa Sets Up Regenerative Medicine Unit to Supply Master Cells, Eyes Distribution
January 12, 2023
- Kaken, Axcelead Hook Up on New Drug Discovery
January 12, 2023
- Mitsubishi Tanabe to End Sales of Lexapro as Deal Expires
January 12, 2023
- Takatsugu Den Tapped as Biogen Japan’s New President
January 12, 2023
- Opdivo Extends Best-Selling Streak to 12 Months: Encise
January 12, 2023
- Eisai Files Alzheimer’s Med Lecanemab in Europe
January 12, 2023
- Kaken Snags Japan Rights to CymaBay Med for Primary Biliary Cholangitis
January 11, 2023
- Otsuka, Schrodinger in Neurology Drug Discovery Collaboration
January 11, 2023
- US FDA Accepts Rexulti sNDA for Alzheimer’s Agitation: Otsuka/Lundbeck
January 11, 2023
- Astellas to Test Selecta’s IgG Protease with Pompe Gene Therapy
January 11, 2023
- NeuroDerm’s Parkinson’s Med Hits Main Goal in PIII
January 11, 2023
- AnGes, miRaX Ink Option Pact for MicroRNA Research
January 11, 2023
- Forxiga Now Available for Heart Failure Regardless of LVEF
January 11, 2023
- AbbVie, Eisai to End Humira Copromotion in June
January 11, 2023
- Japan Ethical Drug Sales Up 2.1% in November: Crecon
January 11, 2023
- Official Margin Proposal Only Realistic for Partial Introduction: Crecon President
January 10, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…